Multicenter Study on the Safety and Efficacy of First-Line Nivolumab-Combination Chemotherapy in Patients Aged 75 Years and Older with Unresectable Advanced or Recurrent Gastric Cancer
First-line chemotherapy with nivolumab is safe and effective in patients aged ≥75 years with a good performance status, as in younger patients, suggesting that it is a valid treatment option for the former subgroup.
Authors
- Nobuhiro Nakazawa (ORCID: https://orcid.org/0000-0001-8705-2150)
- Hisashi Shimizu (ORCID: https://orcid.org/0000-0002-8494-8901)
- Hisashi Hosaka
- Kengo Kasuga (ORCID: https://orcid.org/0000-0001-6949-7682)
- Yuji Kumakura (ORCID: https://orcid.org/0000-0003-4890-3789)
- Kenji Nakazato
- Naritaka Tanaka
- Toshiki Yamashita
- Daisuke Yoshinari
- Akiharu Kimura
- Kyoichi Ogata
- Akihiko Sano
- Takuhisa Okada
- Takuya Shiraishi
- Kana Saito
- Hiroshi Saeki
- Ken Shirabe
- Yasunari Ubukata
Institutions
- Gunma University (JP)
- Maebashi Red Cross Hospital (JP)
- National Hospital Organization Takasaki Medical Center (JP)
- Japanese Red Cross Kochi Hospital (JP)
- Japan Community Healthcare Organization (JP)
- National Hospital Organization (JP)
- Fuji Heavy Industries Health Insurance Society Ota Memorial Hospital (JP)
- Isesaki Fukushima Hospital (JP)
- Hyogo Prefectural Cancer Center (JP)
- Isesaki Municipal Hospital
- Toto (Japan) (JP)
Publication Details
- Journal
- Oncology
- Published
- 2026-01-12
- DOI
- https://doi.org/10.1159/000550345
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00